Galderma Group AG (GALD) AI Stock Analysis

• Market Cap: CHF34.21B
• Dividend Yield: 0.1%
• Average Volume (3M): 272.16K
• Price to Earnings (P/E): 104.1
• Beta (1Y): 0.96
• Revenue Growth: 6.22%
• EPS Growth: N/A
• Country: CH
• Employees: 6,545
• Sector: Healthcare
• Sector Strength: 45
• Industry: Household & Personal Products
• EPS (TTM): 1.11
• Shares Outstanding: 237,897,630
• 10 Day Avg. Volume: 301,334
• 30 Day Avg. Volume: 272,157
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF147.73
• Price Target Upside: 2.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 71 Outperform
• Price Target: CHF134.00 ▼(-6.94% Downside)

Galderma Group AG's stock score is primarily driven by strong financial performance and positive technical indicators. However, the high P/E ratio and low dividend yield suggest potential overvaluation, which tempers the overall score.

Positive Factors

Revenue Growth

The 21% revenue growth indicates strong demand for Galderma's products, enhancing its market position and supporting long-term business expansion.

Cash Flow Generation

Strong cash flow generation ensures Galderma can fund operations and growth investments, providing financial stability and flexibility.

Profitability

High profit margins reflect operational efficiency and pricing power, contributing to sustainable profitability and competitive advantage.

Negative Factors

Debt Levels

While debt levels have improved, historical high debt poses a risk, potentially impacting financial flexibility and increasing vulnerability to market changes.

Income Volatility

Income volatility can lead to unpredictability in financial performance, affecting investor confidence and strategic planning.

Historical Cash Flow Volatility

Volatile cash flow history may challenge consistent funding of operations and growth, requiring careful management to maintain stability.

Galderma Group AG Business Overview & Revenue Model

Company Description

Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

How the Company Makes Money

Galderma Group AG generates revenue through multiple streams, primarily driven by its three core business units: prescription drugs, aesthetics, and consumer care. The prescription drugs segment includes dermatological treatments for skin conditions such as acne, rosacea, and psoriasis, which are sold to healthcare providers and pharmacies. In the aesthetics segment, Galderma offers products like dermal fillers and botulinum toxins, marketed to dermatologists and aesthetic practitioners for cosmetic enhancements. The consumer care segment includes over-the-counter skincare products that are sold directly to consumers through retail and online channels. Galderma's earnings are bolstered by strategic partnerships and collaborations with healthcare professionals, as well as ongoing investments in research and development to create innovative solutions that meet the evolving needs of the dermatology market.

Galderma Group AG Financial Statement Overview

Summary

Galderma Group AG exhibits strong financial health with significant revenue growth and improved profitability metrics. The balance sheet reflects solid equity and manageable debt levels, contributing to stability. Cash flow generation is strong, supporting operational needs and growth investments. Despite past volatility in income and debt levels, current trends indicate a positive outlook.

Income Statement

Galderma Group AG has shown significant improvement in revenue growth, with a 21% increase from the previous year. The gross profit margin is strong at 69.5%, and the net profit margin has turned positive, indicating improved profitability. EBIT and EBITDA margins suggest robust operational efficiency. However, fluctuations in past net income pose a concern for stability.

Balance Sheet

The company's debt-to-equity ratio stands at a conservative level, indicating a balanced leverage position. The equity ratio of 61.7% showcases financial stability and strong equity base. Return on equity has improved, reflecting better profitability for shareholders. Past high levels of debt require ongoing monitoring despite improvements.

Cash Flow

Galderma's cash flow performance is commendable, with free cash flow showing robust growth. The operating cash flow to net income ratio is strong, indicating efficient cash conversion. Free cash flow to net income ratio is positive, but historical volatility in free cash flow growth necessitates cautious optimism.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.44B	3.67B	3.59B	3.12B
Gross Profit	3.08B	2.63B	2.45B	2.18B
EBITDA	959.00M	690.44M	592.24M	476.06M
Net Income	231.00M	-48.11M	-94.07M	-141.07M
Balance Sheet
Total Assets	12.62B	10.49B	11.49B	11.45B
Cash, Cash Equivalents and Short-Term Investments	457.00M	309.35M	216.59M	261.68M
Total Debt	2.76B	4.13B	5.23B	5.18B
Total Liabilities	4.83B	5.97B	7.35B	7.31B
Stockholders Equity	7.79B	4.52B	4.13B	4.14B
Cash Flow
Free Cash Flow	213.00M	37.09M	-46.03M	61.90M
Operating Cash Flow	488.00M	139.11M	106.30M	178.92M
Investing Cash Flow	-326.00M	-156.10M	-70.48M	-487.76M
Financing Cash Flow	-58.00M	142.00M	-68.86M	290.01M

Galderma Group AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 144.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALD, the sentiment is Positive. The current price of 144 is above the 20-day moving average (MA) of 141.88, above the 50-day MA of 134.39, and above the 200-day MA of 110.43, indicating a bullish trend. The MACD of 3.46 indicates Positive momentum. The RSI at 61.96 is Neutral, neither overbought nor oversold. The STOCH value of 48.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:GALD.

Galderma Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NOVN	77 Outperform	186.08B	16.18	32.52%	3.58%	9.36%	-14.82%
ROG	74 Outperform	212.29B	22.07	26.06%	3.66%	4.77%	-11.07%
GALD	71 Outperform	CHF34.21B	104.07		0.10%	6.22%	―
STMN	71 Outperform	14.51B	36.99	19.03%	1.04%	4.49%	45.08%
ALC	66 Neutral	30.62B	32.32	4.72%	0.46%	1.60%	-4.40%
SDZ	54 Neutral	20.97B	105.58	0.01%	1.26%	0.00%	0.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%